Artificial intelligence used to predict how cancers will evolve and spread
‘With this tool we hope to remove one of cancer’s trump cards’
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Scientists have used artificial intelligence to predict how cancers will progress and evolve, which could help doctors design the most effective treatment for each patient.
A team led by the Institute of Cancer Research, London (ICR) and the University of Edinburgh developed a new technique known as Revolver (Repeated evolution of cancer), which picks out patterns in DNA mutation within cancers and uses the information to forecast future genetic changes.
They said the ever-changing nature of tumours is one of the biggest challenges of treatment – with cancers often evolving to a drug-resistant form.
But if doctors can predict how a tumour will evolve, they could intervene earlier to stop cancer in its tracks before it has had a chance to evolve or develop resistance, increasing the patient’s chances of survival.
The team also found a link between certain sequences of repeated tumour mutations and survival outcome.
This suggests that repeating patterns of DNA mutations could be used as an indicator of prognosis, helping to shape future treatment.
For example, researchers found that breast tumours which had a sequence of errors in the genetic material that codes for the tumour-suppressing protein p53, followed by mutations in chromosome 8, survived less time than those with other similar trajectories of genetic changes.
The team developed a new machine-learning technique which transfers knowledge about tumours across similar patients.
This method identifies patterns in the order that genetic mutations occur in tumours that are repeated both within and between patients’ tumours, applying one tumour’s pattern of mutations to predict another’s.
Researchers used 768 tumour samples from 178 patients reported in previous studies for lung, breast, kidney and bowel cancer, and analysed the data within each cancer type respectively to accurately detect and compare changes in each tumour.
By identifying repeating patterns and combining this with current knowledge of cancer biology and evolution, scientists could predict the future trajectory of tumour development.
If tumours with certain patterns are found to develop resistance to a particular treatment, this novel methodology could be used to predict if patients will develop resistance in the future.
The research is published in the journal Nature Methods.
Dr Andrea Sottoriva, who led the study and is team leader in evolutionary genomics and modelling at the ICR, said: “We’ve developed a powerful artificial intelligence tool ... with this tool we hope to remove one of cancer’s trump cards – the fact that it evolves unpredictably, without us knowing what is going to happen next.
“By giving us a peek into the future, we could potentially use this AI tool to intervene at an earlier stage, predicting cancer’s next move.”
ICR chief executive Professor Paul Workman said: “Cancer evolution is the biggest challenge we face in creating treatments that will work more effectively for patients.
“If we are able to predict how a tumour will evolve, the treatment could be altered before adaptation and drug resistance ever occur, putting us one step ahead of the cancer.”
Press Association
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments